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Introduction 
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INTRODUCTION 
 
Epilepsy is a commonly encountered neurological condition 
characterised by recurrent episodes of unprovoked seizures.  Epilepsy acts 
as a broad terminology that includes any abnormal mechanism in brain 
which cause an electrical short circuit or electrical storm that manifests as 
seizure1. Epilepsy affects both adults and children. The terminology 
“Epilepsy” has been used since 500 BC which literally means “to attack or 
assault”.  In ancient times, people with epilepsy were considered as being 
possessed by evil spirits and it was called “the sacred disease”. Theories on 
the etiology of epilepsy had been multidimensional from invasion by 
demons to shifting lunar phases. So it is evident that since olden days the 
association between seizures and cyclicity and between epilepsy and gender 
had been suspected but on different grounds from our understanding today. 
Epileptic seizures can occur with wide variation in presentation and to 
provide effective appropriate treatment, systematic precise classification of 
epilepsy is mandatory. The widely used currently valid ILAE classification 
of epileptic seizures was proposed in 1981 which is based on EEG and 
semilogy. Seizures are mainly divided into partial and generalized seizures, 
but some are unclassified1. 
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 There are certain types of epileptic seizures which occur in clusters 
during a particular period. The classical example of them is Catamenial 
epilepsy. The word “catamenial” is derived from a greek word 
“Katamenios” which means monthly2. Antyllus, who was a contemporary of 
Galen and one of the eminent surgeons of ancient times, wrote, “… the 
moon rather moistens, and for this reason it makes the brain relatively liquid 
and the flesh putrid which renders the bodies of people who live in a clear, 
cold air moist and dull and for the same reason stirs up heaviness in the head 
and epilepsies”2. During middle ages, a vapour emanating from the uterus 
was believed to be triggering the seizures. At a conference in Royal Medical 
and chirurgical society in 1857, Sir Charles Locock was the first to describe 
the association between seizure clusters and menstrual cycle. He named that 
as Hysterical epilepsy (from the greek word “Hystera” which means 
“uterus”) which occurred only in women and he also noted the regularity of 
recurrence associated with the menstrual cycle. Gowers presented  one of 
earlier collection of  menstruation cycle related seizure clusters affecting 
about forty six among eighty two women in 18813.  
 
 The common definition of catamenial epilepsy is, “the seizure 
clusters occurring  around menstrual cycle or an increased seizure frequency  
during certain phases of menstrual cycle”4.  Some female sex hormones and 
certain steroid gonadal hormones have neuroactive properties that can 
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trigger seizures. Though there are many subtypes in catamenial epilepsy, 
neurosteroids have been found to influence the seizure clusters in women 
who have normal 28 day menstrual cycles who suffer during the 
perimenstrual period. It is thought that progesterone derived neurosteroids 
withdrawal causes enhanced stimulation or excitability of cerebral cortex 
which predispose to seizures. Varied concentrations of anticonvulsants 
during the different phases of menstrual cycle also cause increased seizure 
susceptibility5.  
 
 Catamenial epilepsy has been observed in 10% - 70% of epileptic 
women with recurrent exacerbations6. There is a wide percentage of 
prevalence of catamenial epilepsy as reported by many studies due to self-
observed reports, seizure-menstrual cycle diaries of women with 
pharmacoresistant and refractory epilepsy6. But this entity has gained much 
attention and awareness though there is no lucid or globally accepted criteria 
for diagnosing   catamenial epilepsy. 
 
 
 
 
 
 
 
 
 
 
Aim of Study 
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AIM 
 
1. To assess the prevalence of catamenial epilepsy among women 
attending epilepsy clinic of our institution. 
 
2. To classify the women with catamenial epilepsy according to the 
phase of menstrual cycle in which the seizure clusters occur  
 
3. To analyse the seizure dispersion during menstrual cycle in 
women with recurrent epilepsy. 
 
4. To assess the serum estradiol and serum progesterone level of 
women with recurrent seizures during mid-luteal phase of the 
menstrual cycle. 
 
 
 
 
 
 
 
 
 
Review of the Literature 
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REVIEW OF LITERATURE 
 
THE GONADAL HORMONES 
 
OESTROGENS 
 Oestrogens are produced in both ovarian and extraovarian tissues. 
The principal oestrogen synthesised in ovary is 17 beta oestradiol.  The 
oestradiol is predominantly synthesised in granulosa cells of ovaries. 
Oestrogens are produced by the mechanism of aromatization of androgens. 
When these enzymes have hyperactivity it causes “oestrogenization”.  
Oestrogens promote the tissues involved in reproduction to develop and the 
vaginal epithelium and uterine endometrium to proliferate. The myometrium 
becomes mature and the ducts of breasts proliferate.  Oestrogens aid in the 
anabolic effect on bone and cartilage thereby promoting growth.  They are 
also important for the development of secondary sexual characteristics of 
female7.  
 
PROGESTERONE 
Progesterone is produced and secreted by corpus luteum.  It is 
metabolised in the liver. It requires concurrent action of oestradiol for 
appropriate effect. Progesterone aids in reduction of vaginal epithelial 
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proliferation and thus converts the proliferative uterine epithelium to 
become secretory. The development of acinar part of breast glands is 
stimulated by progesterone7.  
 
PUBERTY 
From the eighth year of life in women, there is a gradual progressive 
increase in the pituitary gonadotropic hormones thereby causing menarche 
which occurs usually between 11 and 16 years of age7.  
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THE MENSTRUAL CYCLE 
Once menarche is attained, the menstruation occurs in a regular 
cyclical pattern.  GnRH, the hormone secreted from the hypothalamus in 
pulses every 1 to 2 hours intervals.   GnRH stimulates the release of 
pituitary hormones. The menstrual cycle usually occurs as 28 day cycle but 
may range from 21 to 35 days. On day 1, the menstrual bleeding occurs and 
continues for about 5 days. At the same time, the follicular phase starts and 
the endometrium slowly progresses inorder to receive a fertilized ovum. The 
follicle undergo maturation  under the influence of  FSH. The blood supply 
to ovaries increases and the follicle that undergoes maturation  produces 
oestradiol in increased amount.  
 
 On day 13, the concentration of oestradiol reaches peak and by 
positive feedback mechanism the GnRH and LH is secreted. This causes LH 
to reach its peak for the ovulation to occur. During this time, the body 
temperature increases by about 0.5 degree Celsius. The luteal phase occurs 
between days 14 and 28 of the menstrual cycle. During the luteal phase the 
corpus luteum is formed. The corpus luteum mainly produces progesterone 
and to some extent oestradiol also. If pregnancy does not occur, the corpus 
luteum gradually involutes. During days 27 and 28 of menstrual cycle, there 
is decrease in oestradiol and progesterone secretion. Then the spiral 
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arterioles undergo constriction . so the endometrium undergo ischemia and 
desquamation thus causing menstruation7.  
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INFLUENCE OF HORMONES ON EPILEPSY 
 
 The gonadal hormones have been found to have different effects on 
the susceptibility of seizures in women. Their effects are described below: 
 
OESTRADIOL 
 According to Logothetis and Harner (1960) , “ the oestradiol 
administration to ovariectomized rats resulted in proconvulsant effects”. The 
studies done earlier depict that the oestrogens act on the cerebral cortex 
directly and lead to epileptogenic effects8. Similar studies were done by 
Woolley and Temiras (1962), Marcus et al (1966).  Nicoletti et al, (1985) 
and Woolley (2000) in their study hypothesised, “ oestradiol also potentiates 
seizures triggered  by pentyletetrazol9 .  Smith and his colleagues  along 
with Wong and Moss (1994) proved the excitatory effects of oestrogens 
which can be partially explained by their ability to enhance glutamate-
receptor excitatory neurotransmission and decrease gamma amino butyric 
acidergic inhibition. The oestradiol has direct action of neurons in the limbic 
system, cerebral cortex and the parts of brain that has increased seizure 
susceptibility10. Thus oestrogen has pro-convulsive effect and this is thought 
to be the cause of variation in seizure propensity during different phases of a 
woman’s life after menarche.  
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PROGESTERONE 
 Hans Selye et al first identified the anticonvulsant effect of 
progesterone in the PTZ test during 194210. Many similar studies on both 
animals and humans, were then published later on the anticonvulsant 
properties of progesterone by Craig and Deason (1968), Landgren et al 
(1978), Herzog (1995), Lonsdale and Burnham (2007), Tauboll et al 
(1993)11.  The progesterone and its metabolites have influence over the brain 
excitability by acting though steroid receptor or GABA receptor- chloride 
ionophore complex.  The progesterone with its metabolites act similar to 
barbiturates but the site of action is not the same. Barker et al has shown,” 
the steroids prolong the effective open time of chloride channels, thereby 
inhibiting the excitation of neurons”.  So progesterone affects the excitatory 
ability of brain along with GABA effect. Smith et al (1987), “after systemic 
or topical application of steroid in purkinje cells from cat, both progesterone 
and several metabolites decreased glutamate responsiveness.”12 According 
to Mattson et al (1984) and Herzog (1995), progesterone therapy has been 
beneficial in the treatment of catamenial epilepsy.13 
 
 
 
11 
 
DEFINITION AND PATTERNS OF CATAMENIAL EPILEPSY 
 
 Catamenial Epilepsy is defined as cyclical increase in seizure 
frequency during or around the time of menstrual periods. Duncan et al 
(1993) defined, “Catamenial epilepsy as having 75% of seizures during a 10 
day period of menstrual cycle beginning 4 days before menstruation”.  
Newmark and Penry (1980) defined, “ perimenstrual catamenial epilepsy as 
epileptic seizures occurring in women of fertile age exclusively or 
significantly more often during a 7-day period of the menstrual cycle, 
beginning 3 days before menstruation and ending 4 days after its onset”14. 
Herzog et al. (1997) defined, “ catamenial epilepsy as a greater than average 
seizure frequency during perimenstrual or periovulatory periods in normal 
ovulatory cycles and during the luteal phase in anovulatory cycles”14. All 
the above definitions are arbitrary, not definite, variable and less uniformity 
in definition. According to Reddy (2007), “a two-fold or greater increase in 
seizure frequency during a particular phase of the menstrual cycle may be 
defined as catamenial epilepsy”15. This explanation can be used as a 
standard criterion in studies to analyse the pathophysiology and treatment of 
catamenial epilepsy. By using this criteria, about one third of women with 
intractable epilepsy would be classified under the category of catamenial 
epilepsy. By adopting a standard nomenclature, greater uniformity may exist 
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in studying the pathogenesis and treatment of catamenial seizure 
exacerbation. 
 
Herzog et al, in his study classified catamenial epilepsy into three patterns: 
1. Perimenstrual (C1 ) – Days -3 to 3 
2. Periovulatory (C2 )  - Days 10 to -14 
3. Luteal (C3) -  Days 10 to day 3  
 
 “In the above classification , Day 1 denotes the first day of menstrual 
flow and ovulation is presumed to occur 14 days prior to onset of the next 
cycle (-14). The above mentioned patterns were demonstrated by charting 
the menses and seizure occurrence and estimating the mid-luteal serum 
progesterone level to differentiate  between normal and inadequate luteal 
phase cycles (<5ng/ml).  
 
 Seizure exacerbation around the time of menstruation or ovulation 
occurs in women with normal menstrual cycles”16. Women with abnormal 
menstrual cycles may have exacerbation in the luteal phase of the menstrual 
cycle. This pattern is very difficult to identify because the time of seizure 
exacerbation is prolonged and not focused. These women have anovulatory 
cycles and inadequate luteal phase syndrome. As they do not ovulate, there 
is no corpus luteum (derived from the egg leaving the ovary) formation 
during the luteal phase of the menstrual cycle and hence progesterone is not 
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secreted.The changes in oestrogen and progesterone levels during the 
menstrual cycle influence the seizure pattern in epileptic women.  In fact, 
the neuronal excitability is affected by oestrogen and progesterone. In many 
men and women, seizures do not occur in a random manner. There exists a 
tendency for the seizures to occur in clusters in about 50% of epileptic 
patients.  The seizure clusters occurring with a specific periodicity in 
relation to the menstrual cycle,  is called Catamenial Epilepsy. This may 
occur due to the neuroactive steroid hormones and the rhythmic variation of 
the gonadal hormonal levels. So the gonadal hormones secreted during 
menstrual cycle have effect on the cluster of seizures. The seizure frequency 
during the ovulatory cycles has a direct proportional association with serum 
estradiol/progesterone ratio.  The ratio is at its peak before ovulation and 
during menstruation. The ratio is low at early and middle of the luteal phase 
of menstrual cycle. The seizure clusters during the premenstrual period is 
due to the withdrawal of progesterone. In catamenial epilepsy, the seizures 
tend to occur during particular phase of menstrual cycle. The increased 
seizure frequency during the period just prior to menstruation is the 
commonest type of catamenial epilepsy. The alterations caused by oestrogen 
as well as progesterone in catamenial epilepsy has been studied and 
published by many investigators. But there lie many controversies and 
differences of opinion in the proposed pathogenesis of catamenial epilepsy.  
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Assessment of the levels of oestrogen and progesterone in epileptic women 
with catamenial exacerbation is important. Though the proconvulsive effect 
estrogen is known, Logothetis et al., in his study could not confirm the 
suggestion that increased levels of estrogen are the cause of catamenial 
exacerbation by estimating the ovarian hormone levels during the menstrual 
cycle of epileptic women. Pennell et al also could not substantiate the 
association between the seizure clusters and the serum levels of oestrogen 
and progesterone in women with perimenstrual seizures. But there are a few 
studies which have demonstrated the significant reduction in the frequency 
of epileptiform discharges with intravenous progesterone infusions in a few 
patients17. All these studies emphasise the need of analysing the exact action 
of estradiol and progesterone in women with catamenial and non-catamenial 
epilepsy.  
 
 The prevalence of catamenial epilepsy occurs between ten and 
seventy percentage of epileptic women. This wide range is because of the 
lack of specific criteria to define catamenial epilepsy.  However, the ideal 
definition of catamenial epilepsy would be, the seizure clusters occurring 
during or around the time of menstruation. It can occur in any type of 
seizures. 
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 The wide range of prevalence may be due to the criteria of analysis 
that differs which includes cyclical pattern noted by the patients themselves, 
the seizure clusters noted down in the menstrual cycle-seizure dairy adviced 
to be maintained by the patients and other vague details of seizures 
occurring during the middle of the menstrual cycle which could be due to 
the increase of oestrogen levels before ovulation, without increase in 
progesterone level till ovulation. Actually Seizures do not occur during the 
middle of the luteal phase as the levels of progesterone are high. 
 
 Herzog et al had studied on catamenial epilepsy and the classified 
three distinct patterns of catamenial exacerbation : 
1. Perimenstrual (C1 – days -3 to 3) 
2. Periovulatory (C2 – days 10 to 13) in normal menstrual cycle 
3. Luteal (C3 – days 10 to days -3) in inadequate luteal phase cycles 
 
 In this classification, day 1 is the first day of menses and in normal 
menstrual cycle ovulation is presumed to occur in and around fourteen days 
prior to the onset of subsequent cycle. The following are the ways to 
demonstrate these three patterns of catamenial epilepsy : 
 
1. Noting down the dates of menses and the seizures 
2. Assessing the serum progesterone levels during the luteal phase to 
differentiate between normal and abnormal luteal phase. 
16 
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PATHOPHYSIOLOGY 
 Catamenial epilepsy is believed to occur due to rhythmic and cyclic 
variations of the gonadal hormone levels and the drug metabolism. The 
epileptic women with catamenial exacerbation have their seizure clusters at 
or shortly after menarche. They show excessive EEG activity during the 
menstrual cycle. Oestrogen increases the seizure propensity and 
Progesterone decreases it. Progesterone and estrogen influences the 
development and plasticity of neurons in diffuse cerebral and brainstem 
areas by regulating the synthesis, release and transport of certain 
neurotransmitters like GABA, glutamate and by altering the brain 
excitability18. Particularly during two specific times of menstrual cycle, the 
seizure cluster frequency increases, during the days prior to menses when 
progesterone level is low and then before ovulation when the oestrogen 
level is high. The frequency of seizures also increases when the cycles are 
anovulatory during which time the progesterone levels are again low. In 
women with normal ovulatory cycles, the increased values of estradiol and 
progesterone ratio prior to the onset or during menstruation may be the 
reason behind the seizures. When the progesterone action no longer exists, 
same as that when benzodiazepines are stopped suddenly in a patient with 
epilepsy, the seizure exacerbation might occur in the premenstrual period. 
During the time before ovulation, the levels of oestradiol increase and this 
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might lead on to seizure exacerbation during the periovulatory period. The 
luteal phase is free of seizure or rarely the seizures occur as the progesterone 
is at its peak compare to oestrogen. During anovulatory cycles, the luteal 
phase has low levels of progesterone and so the seizure frequency hikes up 
during the premenstrual period as the oestrogen level increases during the 
middle of menstrual cycle but without increase in progesterone level. In 
some healthy women with normal menstrual cycle, 8-10% has anovulatory 
cycles. Several studies suggest the presence of different types of cyclic 
rhythmic pattern of seizures in women. So, the type of treatment option for 
catamenial epilepsy also differ and depend upon the exact phase of the 
menstrual cycle the seizure clusters occur.  
 
 According to Quigg et al, the seizure frequency may also be 
influenced by age of the patient as age has modulatory effect on the 
hypothalamic-pituitary-gonadal axis through various external factors the 
patients are exposed19.   
 
 Pregnanolone, the endogenous neurosteroid  level may decrease when 
the progesterone levels decrease before menstruation thereby decreasing the 
GABAergic effects and causing seizure exacerbation.  
 
 According to Rosciszewka, Bunter, Guz and Zawisza (1986) , “the 
seizure incidence during the menstrual cycle is connected with a deficit of 
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progesterone rather than elevated oestrogen levels. The lowest number of 
seizures was noted when progesterone reached its highest level”21. The 
progesterone due to its protective effect on brain may be the strategy to be 
used to treat catamenial epilepsy. Females with so-called catamenial 
epilepsy had premenstrual tension more frequently. This difference is 
connected with greater hormonal disturbances and changes in water 
electrolyte balance.  
 
 The serum levels of anticonvulsants also fluctuate at different phases 
of menstrual cycle. The decrease in levels of phenytoin and the association 
with increased seizure frequency have been demonstrated during menstrual 
cycle.  The reduction of oestrogen and progesterone could enhance the 
production of the monooxygenase enzymes in liver thereby increasing the 
seizure propensity. During the times of seizure exacerbation the serum 
levels of anticonvulsants may be measured and alteration in the dosage 
accordingly may be made to achieve seizure control. 
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EFFECTS OF OESTROGENS 
 
 The oestrogens have proconvulsant properties in animals and humans 
According to Terasawa and Timiras, “in female mice the threshold level of 
seizures arising from limbic structures are correlated to the levels of 
estrogen  which is evidenced by the enhancement of epileptiform spike and 
wave discharges occurring spontaneously after administration of estradiol. 
During regular menstrual cycles, the seizure threshold has been found to be 
low in hippocampal regions and more in the amygdala.” 22 The 
pathophysiology behind the neuronal excitability caused by estradiol is not 
clearly understood. According to some experimental studies , the action of 
oestrogen on altering the seizure threshold has been influenced by many 
factors like age of the patient, the nature of the receptors of different 
gonadal hormones.  
 
 The major biological effects of estrogen occurs through two different 
oestrogen receptors, ER alpha and ER beta. Estradiol alters the axonal 
plasticity and therefore the number of dendritic spines in the hippocampus 
increase. This causes increased release of mRNA for NMDA receptors 
thereby increasing the excitability of  NMDA receptors .So the amount of 
calcium that enters  increases which is enhanced by the NMDA receptors 
that are excitatory. The estradiol decreases the Glutamic acid decarboxylase 
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(GAD) causing dysregulation of the GAD, which is an important enzyme in 
conversion of glutamate to GABA. Thus, there is enhanced excitatory effect 
in seizure vulnerable regions due to exposure to estradiol.   
 
 In many studies on humans, the direct correlation between the 
clustering of seizures and the oestrogen progesterone serum levels which is 
high during the perimenstural and around the time of ovulation and low 
during the middle of the luteal phase, have been demonstrated.  Logothetis 
et al, demonstrated that the premenstrual increase in seizure frequency by 
intravenous oestrogen injections given to epileptic women showed interictal 
spike and wave discharges in EEG22. This proves that the facilitatory effect 
of oestrogen is responsible for the catamenial seizure exacerbation. In few 
recent researches the scientists used conjugated synthetic oestrogen derived 
from equine sources. The equine oestrogen conjugated with alpha estradiol 
could not show similar exacerbation of seizures. Till early luteal phase of 
menstrual cycle the mid cycle increased level of oestrogen without 
concurrent increase of progesterone is attributed to periovulatory catamenial 
exacerbation. The premenstrual increase in the ratio of estrogen and 
progesterone level is partly responsible for perimenstrual seizure clusters.  
El-khayat et al also proved the presence of higher progesterone levels in the 
perimenstural period and low ratio of oestrogen and progesterone in women 
with catamenial exacerbation. He also demonstrated increased frequency of 
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epileptiform discharges in EEG during menstruation in these women23. 
Estradiol is hypothesised to have influence on the anovulatory cycles but the 
true mechanism of the oestrogens on this entity is not understood clearly.  
According to Osborne and Frye, oestrogen acts by increasing the 5 alpha 
pregnanolone, a metabolite of progesterone in the hippocampus and could 
possibly have an anticonvulsant action. They implanted some wild mice 
with silastic estradiol capsules and did oophorectomy for all those mice 
thereby depleting the 5alpha reductase and then gave intraperitoneal 
injections of pentylenetetrazol (PTZ). They injected the 5 alpha reductase 
with estradiol in certain other ovariectomised mice and then gave PTZ 
injections. Mice with depleted 5 alpha reductase had seizures24. Estradiol 
has influence on GAD and also in the expression of neuropeptide.    
 
EFFECTS OF PROGESTERONE 
 Many studies done on animals and humans demonstrate the 
association of catamenial seizures and the decrease in progesterone level 
before and after menstruation.  
 
 Progesterone is believed to decrease the neuronal firing and the 
epileptiform discharges.  In human studies, progesterone has been found to 
decrease seizure frequency.  In the mid-luteal  phase , when the serum 
progesterone levels the seizures decrease.  Alterations  in serum 
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progesterone levels have been directly proportional to occurrence of 
catamenial seizures.  
 
 According to a recent study which involved transcranial magnetic 
stimulation in analysing the alterations in the cerebral excitability during the 
menstrual cycle, both ovulatory as well as anovulatory could not prove the 
negative effect of progesterone on the excitability of neurons in mice. There 
were no notable differences in the parameters of  transcranial magnetic 
stimulation  when the progesterone levels were low during menstruation and 
rise in levels during the luteal phase of the cycle.25 
 
 The biological actions of progesterone are facilitated by the 
progesterone receptors (PR) which belong to the nuclear receptor group of 
transcription factors. But the anticonvulsant properties of progesterone are 
not linked to the progesterone receptors. The anticonvulsant property of 
progesterone was not decreased in the mice where the progesterone 
receptors were destroyed by mutation of the progesterone receptor gene.  
The allopregnanolone which is a metabolite of progesterone had been 
observed to have anticonvulsant. So the role of the progesterone receptors in 
the propensity of seizures is not fully established.  There is a increase in the 
amount of dendritic spines during the initial period of exposure and then 
there is a fall in the hippocampal dendritic spines and excitatory synapses. 
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Progesterone has antagonistic actions against oestrogen by reducing the 
number of estrogen receptor number26.  
 
NEUROSTEROIDS 
 Allopregnanolone is  the 3 alpha hydroxylated, A-ring reduced 
metabolite of  progesterone. (3 alpha hydroxyl 5 alpha pregnane – 20-one). 
The allopregnanolone and the allotetrahydrodeoxycorticosterone (allo-
THDOC) are  most effective among the numerous endogenous neuroactive 
steroids which has potent effect on membrane excitability. 
Allopregnanolone has no effects as hormone but together with allo-THDOC  
acts as endogenous brain excitability regulator which has anxiolyic, sedative 
and anticonvulsant properties. Allopregnanolone and allo-THDOC cause 
hyperpolarization of the hippocampal and other neurons by GABA mediated 
inhibitory effects. Allopregnanolone  has similar binding capacity as that of 
benzodiazepine , flunitrazepam, etc. Progesterone, which is the parent 
steroid stimulates GABA –induced chloride currents at peak level. Among 
women, the allopregnanolone level correlates well with the progesterone 
serum level during the menstrual cyle and pregnancy. Anyway the action of 
progesterone and allopregnanolone on brain does not only rely upon the 
extra-cerebral production as they are produced in brain themselves. They are 
produced in cortex and hippocampus. But the allo-THDOC is synthesised 
only in the adrenal gland.  Allopregnanolone , allo-THDOC along with 
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other endogenous and synthetic neurosteroids had been demonstrated to 
have anticonvulsant properties against pentylenetetrazol, bicuculine,  and 
kainicacid- induced seizures and against status epilepticus. But they are not 
effective against electric shock and seizures caused by strychnine. 
Allopregnanolone  has less toxicity than clonazepam though  the action in 
same comparatively less effective. The potent action during the middle of 
the luteal phase at the GABA A receptor may be due to the enhanced 
production of delta GABA a receptor subtype by progesterone. The GABA 
A receptor does not respond to benzodiazepines in the late diestrus part due 
to rapid withdrawal of progesterone but not to allopregnanolone . This 
mechanism could be inhibited by the alpha 4 subunit of the GABA A 
receptors. On the contrary, few sulphated neuroactive steroids increase 
neuronal excitability. They are pregnenolonesulfate and 
dehydroepiandrosteronesulfate (DHAS). They cause negative modulation of  
GABA A receptor thereby increasing the neuronal firing and there is also 
NMDA receptor excitation by glutamate. The DHEAS levels are decreased 
by the enzyme-inducers like phenytoin and carbamazepine27.  
 
 Neurosteroids effectively modulates the GABA A receptors function 
particularly the allopregnanolone. So the perimenstural seizure clusters 
might be due to the withdrawal of the anticonvulsant action of 
neurosteroids. Further due to the withdrawal of the neurosteroids the GABA 
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A receptor alpha 4 subunit in the hippocampus increased with reduced 
GABA gated current thereby increasing seizure propensity and there is 
significant changes in the resistance to several groups of anticonvulsants. 
 
 The recently discovered growth factor response factor -3 (Egr 3) is 
believed to have a significant role in the alpha 4 subunit regulation in 
epilepsy animal models. It has been demonstrated that the levels of this 
factor is found to increase after prolonged seizures and also after the actions 
of neurosteroids are withdrawn27.  
 
DIAGNOSIS 
 Catamenial epilepsy may be diagnosed by the evaluation of menstrual 
cycle and the seizure reporting diaries, by characterising the cycle type and 
duration. Few epileptic women have excessive risk of dysfunction of 
ovaries. In a recent study  25% of epileptic women with generalized seizures 
were found to have anovulatory cycles compared to women with focal 
seizures . so the generalised seizures may be considered as predictor for 
ovarian dysfuction which could cause failure of ovulation.  In another 
similar study,  about 40 women out of 100 epileptic women showed 
anovulatory cycles. Analysing multiple successive menstrual cycles is 
mandatory to assess the occurrence of anovulatory cycle. This study proved 
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the seizure clusters more frequently occurring with women having 
anovulatory cycles28. 
 
 The best way to assess if there is worsening of seizures during certain 
phases of menstrual cycle is to have the patient maintain a note of the 
seizure clusters  in relation to her menstrual cycle. Taking the first day of 
menstrual bleeding as the first day of the menstrual cycle, it is divided into 
four phases: 
 
1. Menstrual phase  –  days -3to 3 
2. Follicular phase  –  days 4 to 9 
3. Ovulatory phase  –  days 10 to 16 
4. Luteal phase  –  days 17 to -3 
 
 In each phase of the cycle, the frequency of seizures is assessed.  The 
mean number of seizure episodes in each part of the cycle is assessed and 
compared to that during other parts of cycle. This aids in classifying to a 
particular type oof catamenial epilepsy. Most acceptable definition is , “ a 
two fold or greater increase in average daily seizure frequency during the 
affected part of the cycle in comparison to the remainder of the cycle” 
(Herzog) 
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 If catamenial epilepsy is diagnosed based on the above definition, 
further measures in evaluation to plan the treatment is as follows: 
 
1. To look for midluteal serum progesterone levels (on twenty second 
day of the normal menstrual cycle) 
2. In there is perimenstural exacerbation of seizures, trough antiepileptic 
drug levels to be checked on day 22 when the serum estradiol and 
progesterone levels are at peak and the AED level should within the 
therapeutic range. 
 
 Low AED levels at this period probably because of increased drug 
metabolism can be the cause of the perimenstural catamenial epilepsy. 
 
 Several studies show that in non-epileptic women too there are minor 
EEG variations during the menstrual cycle. In 1942, according to Dusser de 
Barenne and Gibbs,  during the menses and ovulation EEG shows slowing 
of background activity .Other studies showed that there was a decrease in 
the EEG amplitude during the premenstrual and menstrual phases of the 
cycle29. 
 
TREATMENT 
 The management of catamenial epilepsy may be done by adjusting 
the medications the patient is already taking, non-hormonal and hormonal 
29 
 
therapy. If the antiepileptic drug levels were proved to be low during the 
seizure clusters or during particular phases of menstrual cycle , increasing 
the AED dose or adding another AED often a benzodiazepine around that 
particular time would be helpful in decreasing the seizure frequency. In the 
past years, many empirical measures of adjusting the pre-existing AED dose 
or adding another AED mostly a benzodiazepine had been tried in 
management of the catamenial exacerbation. But these studies were not 
randomised or blinded or controlled trials. Aggressive measures like 
hysterectomy or oophorectomy , hormonal manipulation by giving hormone 
containing contraceptive pills , naturally occurring  progesterone and 
clomiphene  have been tried. Other treatment strategies include adding 
acetazolamide to the AED during the perimenstural period.  
 
 Actually there is no particular drug therapy for catamenial epilepsy 
proven till date as this condition is refractory to many therapies. Among the 
variety of therapies proposed, adding  acetazolamide,  benzodiazepines or 
conventional anticonvulsant drugs with dose adjustment during the 
particular phases and hormonal therapies are useful. However, the proof for 
the efficacy of these treatment modalities is still not very clearly established. 
Multicentre trials may be required to assess the effective treatment for these 
women with catamenial exacerbation. 
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NON HORMONAL THERAPY 
ACETAZOLAMIDE  
 Acetazolamide is a potent carbonic anhydrase inhibitor, an important 
key enzyme for sodium bicarbonate reabsorption and balance of water in the 
collecting tubules of the kidney. It is also abundantly present in the brain. 
Acetazolamide is used effectively to control catamenial seizures. It has been 
demonstrated in a study on twenty epileptic women with different types of 
generalised and partial epilepsy  which showed about thirty to forty 
percentage of these women had decrease in seizure clusters  during the 
perimenstural period with acetazolamide. The mechanism underlying the 
action of acetazolamide in catamenial seizures is not clearly understood. But 
it is evident that after some time tolerance to the drug develops thereby 
decreasing its efficacy.  This may be the reason for administering 
acetazolamide in a short term basis for the catamenial epilepsy rather than 
other types of epilepsy.  
 
 Acetazolamide is found to be used for many years for the 
management of catamenial epilepsy. However, the main drawback was the 
reduction in the efficiency of this drug and development of tolerance to the 
drug30.  
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BENZODIAZEPINES 
 Benzodiazepines which include clonazepam , clobazam, have 
allosteric modulating action on GABA A receptor and have wide sprectrum 
of  anticonvulsant property. Clonazepam is commonly used as an add-on 
drug in absence seizures and myoclonic jerks in children. But the main 
disadvantage is the tolerance developed by the patients. Clobazam has been 
widely used for short term in the catamenial seizure, in a dose of 20 -
30mg/kg body weight starting about two to three days prior to day one of 
menstruation inorder to avoid tolerance development which occurs if given 
continuously. Other side effects are severe depression and day time 
sleepiness. The development of tolerance to the drug may be due to long 
term action of neurosteroids which is observed in animal models. 
Benzodiazepines may be theoretically utilised for the prophylaxis of 
catamenial epilepsy. In fact, clobazam which is given for short term is very 
much useful in the treatment of catamenial seizure exacerbations over long 
periods of time with satisfying results31. 
 
HORMONAL TREATMENT 
 Till date only open controlled analyses of progesterone therapy have 
been studied. These studies have shown that the treatment with progesterone 
has considerably reduced the seizure frequency in some women. As the 
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different patterns of catamenial epilepsy respond in a different manner, the 
treatment options are complicated. 
 
MEDROXYPROGESTERONE ACETATE 
 Medroxyprogesterone acetate (MPA) is an oral contraceptive drug 
that has only progesterone. Zimmerman and colleagues (1973) stated that , 
MPA has been demonstrated to produce about 30 – 40% decrease in the 
seizure clusters when studied for about one year. So it is understood that 
chronic MPA treatment can cause reproductive dysfunction in unpredictable 
manner. The underlying mechanism of action of MPA is not well 
established but the progesterone receptors are found to have an infuence in 
the action of catamenial epilepsy.  Contrary to progesterone, MPA is not 
converted to the neurosteroids and so had no modulating action on GABA 
A. So, medroxyprogesterone acetate is a better drug than progesterone 
probably for this particular reason32.  
 
CYCLIC PROGESTERONE THERAPY 
 Progesterone has been found to have anticonvulsant properties in 
women with catamenial epilepsy.  It was earlier considered that along with 
the anticonvulsants progesterone or its metabolites or clomiphene could be 
used concomitantly.  Natural progesterone can be tried in epileptic women 
with catamenial exacerbation and those with impaired luteal cycles. A 
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couple of trials where progesterone given as an add on therapy in women 
with catamenial epilepsy showed significant decrease in the frequency of 
seizure clusters. Some studies on women with abnormal luteal cycles who 
also had catamenial epilepsy about six women out of eight showed 
reduction in seizure frequency with progesterone , about 70% reduction in 
the seizure frequency . Another open trial where progesterone given as an 
add on therapy periodically in one group of women and in another group the 
anticonvulsants alone, there was a 72% of reduction in seizure frequency of 
generalised seizures and 54% of complex partial seizures  in the first 
group33.    
 
 Progesterone is more useful and the efficacy is greater if given during 
the second half of the cycle than just during the premenstrual period and 
then gradually tapered and withdrawn at the end of the menstrual cycle. If 
progesterone is withdrawn rapidly it can lead on to rebound seizure 
exacerbation.  According to a study by Herzog, “the average daily seizure 
frequency per patient after 3 years follow up showed that the 15 women 
who remaind on cyclic progesterone therapy and their original antiepileptic 
drugs continued to show improved seizure control in comparison to their 
own baseline. Three women were entirely seizure –free. Four had total 
seizure reductions of 75 – 99%. Eight had reductions of 50 – 74%. Complex 
partial seizures in these 15 were lower by a statistically significant 62%, 
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secondary generalised seizures by 74%. Antiepileptic drug serum levels 
continued to show no significant change. The three remaining women who 
continued on progesterone therapy had 10 – 50% improvement at the end of 
the original investigation at 3 months and were not considered further 
because they changed antiepileptic drugs” (Herzog)33. The drawback of 
these studies is that the results are also biased by analysing only 15 of the 25 
subjects.  
 
 The study with transcranial magnetic stimulation analysed that 
progesterone increases inhibitory effect in the brain during the premenstrual 
period. Natural progesterone is given thrice daily due to the half-life of 
about 4 to 6 hours. The usual daily dose range from 300 to 600mg. The dose 
and the schedule of the drug should be individualised and based on clinical 
seizure frequency reduction and also serum progesterone levels between 20 
– 40 ng/ml. Progesterone is available in another form in capsule preparation 
that has similar anticonvulsant actions yet it is not fully evident. 
Theoretically, the progesterone in this form passes though the liver first and 
cause the delivery of progesterone and its metabolites  in different 
concentrations33. Side effects occurring with overdosage are excessive 
sleepiness, depression and asthenia,  tenderness of breast , obesity, 
menorrhagia.  The dose of anticonvulsants need to be increased as 
progesterone might increase the liver metabolism and protein binding of the 
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anticonvulsants especially phenobarbitone, carbamazepine and. The use of 
progesterone associated with the anticonvulsant drug level changes has been 
sporadic and not in a predictable way. So the free AED level in serum needs 
to be measured regularly while the patient on progesterone34. 
 
NEUROSTEROIDS 
 Although there are several forms of catamenial epilepsy, 
neurosteroids have been implicated only in the seizure exacerbations that 
occur in the most common situation, which is when women with normal 
menstrual cycles experience seizure exacerbations in the perimenstrual 
period. The neurosteroid withdrawal model of catamenial epilepsy was used 
to investigate therapies for perimenstrual catamenial epilepsy. A key result 
is that conventional antiepileptic drugs, including benzodiazepines and 
valproate, have reduced potency in protecting against seizures during the 
period of enhanced seizure susceptibility following neurosteroids 
withdrawal. This pharmacoresistance seems to mimic the situation in 
women with catamenial epilepsy where breakthrough seizures occur despite 
treatment with antiepileptic drugs. In contrast to the results with 
conventional antiepileptic drugs, neurosteroids, including allopregnanolone, 
THDOC and their 5β-isomers, were found to have enhanced activity in the 
perimenstrual catamenial epilepsy model35. This suggested a “neurosteroid 
replacement” approach to treat catamenial seizure exacerbations. A 
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neurosteroid could be administered in a “pulse” prior to menstruation and 
then withdrawn, or continuously administered throughout the month. While 
intermittent administration at the time of increased seizure vulnerability is 
rational, continuous administration would avoid withdrawal of the 
therapeutic agent, which itself could predispose to seizures36. The 
neurosteroid would be administered at low doses to avoid sedative side 
effects. Such low doses are expected to contribute little anticonvulsant 
activity during most of the menstrual cycle. Patients would still require 
treatment with conventional antiepileptic medications. However, during the 
period of enhanced seizure susceptibility at the time of menstruation, the 
increased potency of the neurosteroid would confer protection against 
perimenstrual seizure exacerbations. It is noteworthy that while the 
anticonvulsant activity of neurosteroids increases in conjunction with 
neurosteroid withdrawal, there is no corresponding increase in side effects 
(mainly sedation), at least as assessed by a measure of motor impairment. 
Therefore, enhanced side effects, which would negate the potential of the 
therapeutic approach, would not be expected to occur36.  
 
GANAXOLONE 
 Ganaxolone is a neuroactive steroid that modulates the GABA A 
receptor complex. It is also a potent synthetic analogue of allopregnanolone 
and is currently under trial. A moderate improvement in seizures was 
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achieved in women with perimenstural seizures treated with ganaxolone 
300mg twice daily from day 21 of the cycle through day 3 of menses 
(McAuley et al. 2001)37. To determine whether the enhanced activity of 
neurosteroids is due to pharmacokinetic or pharmacodynamic factors, brain 
and plasma levels of the neurosteroid ganaxolone (3α-hydroxy-3β-methyl-
5α-pregnan-20-one)  were determined with a liquid chromatography-mass 
spectrometric method. Control and neurosteroid withdrawn animals 
received a single dose of ganaxolone (7 mg/kg, subcutaneously), resulting in 
an elevation in PTZ threshold that peaked at 30 min and returned to baseline 
at 120–180 min. Ganaxolone caused a markedly greater (1.8-fold) elevation 
of PTZ threshold in the withdrawn animals than in controls, indicating a 
greater sensitivity to the anticonvulsant effects of ganaxolone. Surprisingly, 
plasma and brain ganaxolone levels were reduced in withdrawn animals 
(69% of control levels). Adjusting for the reduced brain levels, the 
pharmacodynamic sensitivity to ganaxolone was enhanced 2.3-fold in the 
withdrawn animals compared with controls. There was a significant increase 
in clearance (CL) of ganaxolone in the withdrawn animals, which accounts 
for the reduced plasma and brain levels. Brain levels of ganaxolone reached 
a peak more slowly (Tmax-brain, ~30 min) than in plasma (Tmax-plasma, 
~15 min); the Tmax-brain value corresponds with the peak elevation in 
seizure threshold. These studies confirmed the enhanced anticonvulsant 
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activity of ganaxolone in the rat model of catamenial epilepsy35. The 
enhanced activity occurs in the face of decreased plasma and brain 
ganaxolone levels, indicating a marked increase in pharmacodynamic 
sensitivity. Ganaxolone might be effective in treating catamenial epilepsy 
due to fewer side effects as compared to other hormonal side effects. 
According to a multicentre clinical trial done by Laxer et al demonstrated 
the side effects of ganaxolone were less and ganaxolone was tolerated as 
placebo  in women with catamenial epilepsy38. Moreover, neurosteroid 
withdrawal causes markedly greater seizure provocation in the catamenial 
epilepsy model, consistent with earlier studies demonstrating enhanced 
seizure susceptibility in acute seizure models. In catamenial epilepsy, 
breakthrough seizures occur despite treatment with antiepileptic drugs. 
Previous studies and the new results from Lawrence et al. support the 
potential of neurosteroids as a novel treatment approach for these 
pharmacoresistant seizures39. Although neurosteroids seems to be the most 
direct approach to the treatment of catamenial epilepsy, there is only limited 
anecdotal data available to support their use. No neurosteroids is currently 
approved. In contrast, there is considerable support from human clinical 
trials for the use of adjunctive progesterone in the treatment of 
perimenstrual catamenial epilepsy. It is recommended that the hormone be 
administered during the entire second half of the menstrual cycle and 
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tapered gradually as it is believed that abrupt discontinuation can result in 
rebound seizure exacerbation. Enthusiasm for the use of progesterone in the 
treatment of catamenial epilepsy had been tempered by the lack of data from 
adequately controlled clinical trials.  
 
 Neurosteroids, such as ganaxolone, have not been associated with 
such side effects and may ultimately prove to be superior as a treatment 
approach. In the treatment regimen used in the clinical trials, progesterone is 
administered only after cycle day 14 and is tapered and discontinued during 
days 26 to 28 as it is believed that starting earlier than mid-cycle would 
interfere with normal cycling and lead to irregular bleeding. An advantage 
of hormonally-inactive neurosteroids is that they can be administered 
throughout the cycle, simplifying the treatment regimen. New oral 
preparations of ganaxolone with better bioavailability are under study. 
 
 
 
 
 
 
 
 
 
 
Materials and Methods 
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MATERIALS AND METHODS 
INCLUSION CRITERIA 
 All women who have attained menarche attending Epilepsy clinic in 
our institution with recurrent seizures and taking more than one primary 
anticonvulsant 
 
EXCLUSION CRITERIA 
1. Women who are yet to attain menarche and who had attained 
menopause 
2. Women who are seizure free for more than one year 
3. Seizures with an underlying cause 
4. Women who take single anticonvulsant 
 
STUDY POPULATION 
 100 women with recurrent seizures attending epilepsy clinic who 
have been selected based on our inclusion and exclusion criteria  
 
STUDY PERIOD  
6 months (January 2013 to june 2013) 
 
METHOD 
 All the women included in the study were asked to maintain a diary 
of menstrual cycle, to note down the first day and last day of the menstrual 
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period. They were also asked to note the date and time of occurrence of the 
seizure episode.   
 
 The clusters of seizure occurrence were noted and its relation with 
respect to the phases of menstrual cycle documented.  On the midluteal 
phase (day 21) of the menstrual cycle, Serum estradiol and progesterone 
levels were done in women with catamenial epilepsy done and compared 
with that of their age matched non-catamenial women.  
 
 With the results, the prevalence of catamenial epilepsy among the 
women with recurrent seizures in the reproductive age group will be 
identified and they are categorised into subtypes of catamenial epilepsy. 
 
 
 
 
 
 
 
 
 
 
Observation and Results 
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OBSERVATION AND RESULTS 
 
 
The total number of women with recurrent and refractory seizures – 100 
N = 100 
 
 
PREVALENCE OF CATAMENIAL EXACERBATION 
 
Total patients with cluster of seizures associated 
with menstrual cycle (Catamenial Epilepsy) 
20 
No association between seizures  and menstrual 
cycle (Non-Catamenial women) 
80 
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CLASSIFICATION OF CATAMENIAL EPILEPSY (N = 20) 
 
 
TYPE NUMBER PERCENTAGE 
PERIMENSTRUAL (C1) 16 80 
PERIOVULATORY (C2) 4 20 
PERILUTEAL (C3) 0 0 
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MENSTRUAL CYCLE OF WOMEN WITH CATAMENIAL 
EPILEPSY (N = 20) 
 
REGULAR (28 DAY CYCLE) IRREGULAR 
14 (70%) 6 (30) 
 
 
 
 
 
MENSTRUAL CYCLE IN NON-CATAMENIAL WOMEN (N = 80) 
 
REGULAR (28 DAY CYCLE) IRREGULAR 
68 (85%) 12 (15%) 
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SERUM ESTRADIOL (pg/ml) AND PROGESTERONE LEVELS 
(ng/ml) ON MID-LUTEAL (DAY 21) OF 28 DAY  MENSTRUAL 
CYCLE IN WOMEN WITH CATAMENIAL EPILEPSY AND  
NON-CATAMENIAL EPILEPSY 
 
Sl. 
No. 
CATAMENIAL NON-CATAMENIAL 
Age 
(yrs) 
Estradiol 
(pg/ml) 
Progesterone 
(ng/ml) 
Age 
(yrs) 
Estradiol 
(pg/ml) 
Progesterone 
(ng/ml) 
1 25 160 8.97 26 137 14.33 
2 27 253 9.24 27 135 14.25 
3 19 263 8.07 18 132 14.23 
4 18 196 10.09 19 174 16.69 
5 32 328 8.38 30 139 14.55 
6 35 181 6.32 35 184 12.15 
7 28 330 8.62 28 130 16.64 
8 23 323 8.60 24 175 16.09 
Mean 
+ 
SEM 
25.87 
+ 
5.91 
254.25*** 
+ 
69.30 
8.53*** 
+ 
1.08 
26.625 
+ 
5.476 
150.75 
+ 
22.65 
14.86 
+ 
1.53 
 
  *** P<0.001, pg-Picogram & ng-Nanogram 
 
(Luteal phase normal values: Estradiol -  43.8-211  pg/ml & Progesterone - 1.7-27 ng/ml) 
 
Statistics 
Statistical analysis was performed with Graph Pad statistical software package version 
3.05 (GraphPad Software, Inc , San Diego, California).Hormonal data were analysed 
using one-way ANOVA with Tukey Post test, Values are presented as Mean + SEM, and  
p value of < 0.05 was considered statistically significant. 
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HORMONE LEVELS 
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AGE DISTRIBUTION OF NON-CATAMENIAL WOMEN (N =80) 
 
AGE (YEARS) TOTAL NUMBER PERCENTAGE 
15 – 25 30 37.5 
25 – 35 26 32.5 
35 – 45 14 17.5 
45 – 55 10 12.5 
 
 
 
 
 
 
 
 
 
48 
 
 
 
 
 
 
AGE DISTRIBUTION OF WOMEN WITH CATAMENIAL 
EPILEPSY (N = 20) 
AGE GROUP NUMBER PERCENTAGE 
15 – 25 10 50 
25 – 35 8 40 
35 – 45 2 10 
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TYPE OF SEIZURE AMONG NON CATAMENIAL WOMEN  
(N = 80) 
 
 
TYPE OF SEIZURE NUMBER PERCENTAGE 
Generalised Tonic Clonic 
Seizures 38 47.5 
Absence Seizures 8 10 
Complex Partial Seizures 34 42.5 
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TYPE OF SEIZURES AMONG WOMEN WITH CATAMENIAL 
EPILEPSY 
 
TYPE OF 
SEIZURES 
PERIMENSTRUAL 
(16) 
PERIOVULATORY 
(4) 
Generalised Tonic 
Clonic Seizures 10 (62.5%) 2 (50%) 
Absence Seizures 1 (6.25%) 
 
- 
 
Complex Partial 
Seizures 5 (31.25%) 2 (50%) 
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EEG ABNORMALITIES 
 
EEG FINDINGS 
NON-CATAMENIAL 
WOMEN 
(N = 80) 
CATAMENIAL 
WOMEN 
(N = 20) 
Bursts of spike and wave 
discharges 38 (47.5%) 12 (60%) 
Left temporal spike and 
wave discharges 24 (30%) 5 (25%) 
Right temporal spike and 
wave discharges 10 (12.5%) 2 (10%) 
3 hz/cycle spike and wave 8 (10%) 1 (5%) 
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ANTIEPILEPTIC DRUGS CONSUMED BY WOMEN WITH 
CATAMENIAL EPILEPSY (N = 20) 
 
Phenytoin + Sodium Valproate 5 (25%) 
Phenytoin + Carbamazepine 4 (20%) 
Carbamazepine + Phenytoin + 
Diazepam 3 (15%) 
Phenytoin + Sodium Valproate + 
Carbamazepine 8 (40%) 
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ANTIEPILEPTIC DRUGS CONSUMED BY NON-CATAMENIAL 
WOMEN (N = 80) 
 
Phenytoin + Sodium Valproate 14 (17.5%) 
Phenytoin + Carbamazepine 12 (15%) 
Carbamazepine +Phenytoin + 
Diazepam 5 (6.25%) 
Phenytoin + Sodium Valproate + 
Carbamazepine 49 (61.25%) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Discussion 
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DISCUSSION 
 
 Catamenial epilepsy is one of the rare subtypes of epilepsy that 
occurs specially in women with epilepsy who have exacerbation of seizures 
around specific phases of menstrual cycle. There is a wide variation in 
prevalence of catamenial epilepsy as there are no clear criteria to define or 
diagnose this condition. During recent times with increasing awareness 
regarding the influence of hormones on the neuronal excitability, many 
studies have been done to understand this rare condition. 
  
 Out of 100 women with recurrent seizures, 20 showed catamenial 
pattern of seizure occurrence. These 20 women had seizure clusters 
occurring periodically at a particular phase of menstrual cycle as assessed 
by the seizure –menses diary for six consecutive months. So the prevalence 
of catamenial epilepsy according to our study is 20%. This percentage of 
catamenial pattern as observed in our study is less compared to other recent 
studies. Herzog et al, (2004) in his study showed that 39% had catamenial 
epilepsy. He analysed 89 women with epilepsy who charted their menstrual 
period and seizures for three cycles40.  In a more recent study by El Khayat 
et al, (2008), about 31% of epileptic women showed catamenial seizures23.  
One study done by Duncan et al, showed the  prevalence rate of 12.5% 
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which is much less compared to our study41. Bhazan et al (2005) and Reddy 
et al, (2004) showed that the prevalence of catamenial epilepsy was quite a 
wide range from 10 – 70%15.  This wide range and disparity of prevalence 
of catamenial seizures in various studies  is probably due to absence of a 
precise definition or criteria to define the pattern and absence of a uniform 
methodology in selecting the patients and analysing the seizure cluster 
pattern in relation to various stages of menstrual cycle. There is no 
consensus on analysing the pattern of catamenial seizure occurrence. 
Another reason is that the study population in all these studies represent the 
selected population and the results cannot be generalised for the entire 
population of epileptic women. 
 
 Among the 20 women with catamenial epilepsy, 16 (80%) had 
perimenstrual type of  catamenial epilepsy,  4 (20%) had periovulatory type. 
None of the epileptic women in our study had the third type which is the 
luteal type of  catamenial epilepsy.   This classification was done based on 
the distinct patterns of catamenial epilepsy as explained by Herzog et al 
(1997).  In his study, 59% of women with catamenial epilepsy were under 
the perimenstural category and he concluded this type as the commonest of 
the other types of catamenial epilepsy14. Another study by El Khayat et al 
(2008) also showed similar results. Thus several studies done on the 
classification of catamenial epilepsy reveal that the commonest of the three 
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types is the perimenstrual  (C1) type and next is periovulatory (C2)  type. 
Both these types occur in women with ovulatory menstrual cycle.  Luteal 
type (C3) is very rare and is found in anovulatory cycles. Herzog et al 
(2008) showed in his study that 16.5% of   women with catamenial epilepsy 
had anovulatory cycles and had luteal type of catamenial epilepsy42. Our 
study also showed the Perimenstrual type as the most predominant among 
other types of catamenial epilepsy similar to other studies. We did not fine 
the occurrence of third type the periluteal type of catamenial epilepsy 
among our study population. The third type as such is a rare entity and that 
could be the reason.  
 
 Out of the 20 women with catamenial epilepsy, 14 (70%) had regular 
28 day menstrual cycle and the remaining 6 (30%) had irregular menstrual 
cycle. The women with irregular menstrual cycle also had perimenstural 
type of catamenial epilepsy. In the 80 women in noncatamenial group, 68 
(85%) had regular cycle and 12 (15%) had irregular cycles. There was no 
correlation observed in our study regarding the regularity of the menstrual 
cycle and the prevalence or type of catamenial epilepsy.  Detailed 
background hormonal and gynaecological analysis is required in a bigger 
population to comment on the menstrual cycle periodicity which could have 
an influence over the type of catamenial epilepsy.   
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 On day 21 of menstrual cycle, serum estradiol and progesterone 
levels were analysed in eight women with catamenial epilepsy who had 
regular 28 day menstrual cycle and their age matched controls in the non-
catamenial group.  There was statistically significant increase in the level of 
serum estradiol in the women with catamenial epilepsy compared to the 
noncatamenial group. The progesterone level was significantly low in the 
group of catamenial epilepsy than in the women with the non-catamenial 
epilepsy.  Both serum estradiol and progesterone levels are expected to be at 
the baseline during the 21st and 22nd day of the cycle in a regular 28 day 
menstrual cycle. This period corresponds to the mid-luteal phase of the 
menstrual cycle.  The increase in the oestrogen level which has 
proconvulsant properties and withdrawal of progesterone with 
anticonvulsant properties might support the pathophysiology of catamenial 
epilepsy. Studies done by Herzog et al (1997) and Backstrom (1976) 
showed similar results suggesting the excess estradiol or withdrawal of 
progesterone contribute to catamenial epilepsy43.  In a study done by Zahir 
Hussain (2006) proved statistically significant increase in the level of 
estradiol among catamenial women compared to the age matched non-
catamenial women44.  
 
 Among the women in the noncatamenial group, out of 80, 30 (37.5%) 
were in the age group of 15 -25 years, 26 (32.5%) were within the range of 
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25 – 35 years, 14(17.5%) were in the group of 35 – 45 years and 10 (12.5%) 
women were in the range of 45 – 55 years.  In the catamenial group, out of 
20, 10 (50%) were in the age group of 15 – 25 years, 8(45%) were in the 
group of 25 – 35 years and 2 women (10%) were in the group of 35 – 45 
years.  Majority of  women with catamenial epilepsy were in the age group 
of 15 – 25 years which is the active reproductive period during which there 
are major fluctuations in the gonadal hormones. There was no major 
difference in the age distribution  of the women in the noncatamenial group 
however slight preponderance was observed in the age group of 15 – 25 
years. 
 
 In the catamenial epilepsy group, among the women with 
perimenstrual type, 10 (62.5%) had generalised tonic clonic seizures, 5 
(31.25%) had complex partial seizures and 1(6.25%) had absence seizure. 
Among the women with periovulatory type of catamenial epilepsy, 2 (50%) 
had generalised tonic clonic seizures and 2 (50%) had complex partial 
seizures. There was no specific type of seizure semiology or seizure 
syndrome associated with catamenial epilepsy noted in our study.  
 
 All the women included in our study were on more than one primary 
anticonvulsant. Phenytoin and sodium valproate were taken by 14 (17.5%) 
of women in non-catamenial group and 5 (25%) of women in catamenial 
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group.  Pheynytoin and carbamazepine were taken by 12 (15%) in the non-
catamenial group and 4 (20%) in catamenial group. 49 (61.25%) of women 
in non-catamenial group and 8 (40%) women with catamenial epilepsy were 
on phenytoin, carbamazepine and sodium valproate. 3 women in catamenial 
epilepsy group were on carbamazepine and phenytoin with intermittent 
diazepam but continued to have cyclic seizure exacerbation. 
  
 
 
 
 
 
 
 
 
 
Conclusion 
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CONCLUSION 
 
The following are the observations of our study: 
1. Catamenial epilepsy was observed in 20% of women with recurrent 
and refractory seizures attending the epilepsy clinic in our institution. 
2. The perimenstrual type (C1) was the commonest among the women 
with catamenial epilepsy. 
3. The catamenial epilepsy was commonly found in the age group of 15 
to 25 years in our study. 
4. There was significant increase in the level of serum estradiol level 
and decrease in the level of progesterone among women with 
catamenial epilepsy compared to noncatamenial group.  
5. Majority of women with catamenial epilepsy in our study had 
generalised tonic clonic seizures and no specific seizure type confined 
to any particular type of catamenial epilepsy. 
 
 A wide population of women with epilepsy are treated with multiple 
anticonvulsants and are considered refractory to treatment. The under 
recognition and lack of awareness of  catamenial epilepsy could be one of 
the reasons behind the polytherapy of anticonvulsants in many such women, 
especially in our country. There are very few studies analysing the 
prevalence of catamenial epilepsy in our country. Among the women with 
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pharmacoresistant epilepsy, about one fifth of women according to our 
study fall under the category of catamenial epilepsy where the appropriate 
treatment strategy would reduce the burden in the lives of these epileptic 
women.  
 
Our study proposes following recommendations: 
1. All epileptic women of childbearing age could be educated to 
maintain an accurate seizure and menstrual diary in order to identify 
and manage the catamenial epilepsy. 
2. It is important to do a precise hormonal analysis in appropriate phases 
of menstrual cycle in women with catamenial epilepsy. 
3. It is also essential to do antiepileptic drug level during the cluster of 
seizures in order to analyse the influence of the gonadal hormones on 
the anticonvulsant drug metabolism during various phases of 
menstrual cycle. 
 
 Thus, the recognition and appropriate management of catamenial 
epilepsy in women with refractory epilepsy would be an ideal solution in 
reducing the seizure clusters and improving their quality of life.   
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PROFORMA 
Name:     Age:    MIN no: 
Type of Seizure:        
Duration of illness: 
Frequency: 
Any specific precipitating factors: 
Anticonvulsant: 
Compliance: 
Date of Last episode: 
First day of last menstrual period: 
Last day of last menstrual period: 
Menstrual cycle : Regular / Irregular 
Premenstrual symptoms: 
Marital History: 
Details of child birth: 
General examination : 
Examination of CNS : 
EEG: 
Neuroimaging: 
Hormone level: 
 
  
MASTER CHART 
 
  
  
 
  
  
KEY TO MASTER CHART 
 
0   –  No 
1   –  Yes 
GTCS   –  Generalised tonic clonic seizures 
CPS   –  Complex partial seizures 
CE   –  Catamenial Epilepsy 
NCE   –  Non catamenial Epilepsy 
REG   –  Regular menstrual cycle 
IRREG  –  Irregular menstrual cycle 
EST   –  Estradiol (pg/ml) 
PRG   –  Progesterone (ng/ml) 
BSW   –  Bursts of spike and wave discharges  
LTSW  –  Left temporal spike and wave discharges 
RTSW  –  Right temporal spike and wave discharges 
3SW   –  3 cycles per second spike and wave discharges 
PHN   –  Phenytoin 
SVP   –  Sodium valproate 
CBZ   –  Carbamazepine 
DZM   –  Diazepam 
 
 
 
